Edward Stadtmauer
, Activity Director · University of Pennsylvania Health System
Credentials: · · · · ·
History
- Present
Hematologic Malignancies Section · Perelman School of Medicine at the University of Pennsylvania
- Present
Perelman School of Medicine at the University of Pennsylvania · University of Pennsylvania Health System
- 1986–1989
Bronx Municipal Hospital
1975–1979
Research
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
New England Journal of Medicine · 2005 · 2,069 citations
CRISPR-engineered T cells in patients with refractory cancer
Science · 2020 · Co-first of 41 authors · Corresponding · 1,187 citations
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
New England Journal of Medicine · 2007 · 1,038 citations
75 papers
63 papers
60 papers
47 papers
46 papers
- DT
39 papers · 6 as a fellow
38 papers
38 papers
Grants
- 2001–2031
BMT CTN Core- University of Pennsylvania Abramson Cancer Center
National Heart, Lung, and Blood Institute · UG1
Contact PI · $2M · University of Pennsylvania
- 1997–2027
Abramson Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.3M · University of Pennsylvania
- 2017–2023
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
National Cancer Institute · P01
Project lead · $2.6M · University of Pennsylvania
- 2015–2018
National Cancer Institute · R21
PI · $400.7K · University of Pennsylvania
Clinical trials
- 2022–2023
Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma
Principal investigator · Completed
Abramson Cancer Center at Penn Medicine
- 2018–2022
Principal investigator · Completed · Phase 1
Sorrento Therapeutics, Inc.
- 2018–2020
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Principal investigator · Terminated · Phase 1
University of Pennsylvania
- 2014–2018